Overactive Bladder VL

Frailty, Socioeconomics, and Specialist Access Drive Overactive Bladder Care Disparities - Ekene Enemchukwu

Details
Ruchika Talwar interviews Ekene Enemchukwu about her Medicare-based study examining disparities in overactive bladder (OAB) treatment, particularly focusing on the utilization of beta-3 agonists versus anticholinergic medications. The research reveals that while frail and older adults are more likely to receive beta-3 agonists, aligning with current guidelines to avoid anticholinergics due to deme...

Making Sense of Advanced Technologies to Integrate into your OAB Program "Presentation" - Kari Bailey, David Sussman & Neil Kocher

Details
At the 2024 LUGPA annual meeting, Kari Bailey, David Sussman, and Neil Kocher discuss advanced overactive bladder therapies, highlighting the shift toward earlier use of neuromodulation and tibial nerve stimulation. They emphasize patient selection, multimodal approaches, and the role of patient navigation in optimizing outcomes. Biographies: Kari Bailey, MD, Anne Arundel Urology, Annapolis, MD Da...

COURAGE Trial: Vibegron for BPH Patients with Persistent OAB Symptoms - David Staskin

Details
David Staskin discusses the COURAGE trial, a phase three study evaluating the efficacy of Vibegron, a beta-3 adrenergic receptor agonist, in men with BPH and persistent OAB symptoms despite alpha-blocker treatment. The study demonstrates significant improvements in various urinary symptoms, including micturitions, urgency episodes, and nocturia. Dr. Staskin highlights the drug's favorable safety p...

Optimizing Overactive Bladder Treatment: Phenazopyridine's Cost-Effective Approach - Anjali Kapur

Details
Anjali Kapur discusses a cost analysis comparing oral Phenazopyridine (Pyridium) to intravesical lidocaine for pain control during Botox injections for overactive bladder. The study finds that using Pyridium is less costly, saving about $98 per visit and potentially $24 million annually if widely adopted. Dr. Kapur highlights the high prevalence of overactive bladder and the increasing use of Boto...

Oxybutynin-Associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment - Beyond the Abstract

Details
Anticholinergic medications have long been mainstays of overactive bladder (OAB) treatment. Oxybutynin, a first-generation anticholinergic, still accounts for more than half of all OAB medication prescriptions, despite associations with impaired memory and cognition, as well as mounting evidence that it may increase the risk of incident dementia. Biographies: Michael Chancellor, MD, Corewell Healt...

Emerging Technologies in Urology: A Glimpse Into Tibial Nerve Stimulation for Bladder Dysfunction Treatment - Diane Newman & Howard Goldman

Details
In this discussion, Diane Newman, talks with Howard Goldman about advances in neuromodulation technology for patients with lower urinary tract dysfunction, overactive bladder, and urinary incontinence. Dr. Goldman highlights the potential of implantable tibial nerve stimulation devices, particularly a small device developed by BlueWind Medical. The device, placed next to the tibial nerve, is power...

Revolutionizing Urodynamics: Uromonitor's Comfortable, Real-Life Bladder Pressure Tracking - Diane Newman & Howard Goldman

Details
Diane Newman engages in a discussion with Howard Goldman on the Uromonitor, a non-invasive urodynamic device designed to measure bladder pressures in a more comfortable, natural setting. This innovative device, developed in partnership with Bright Urology and the Cleveland Clinic, is placed in the bladder and allows patients to move freely without external catheters. The Uromonitor, with its "Holt...

Phase 2a Trial Results: Promising Gene Therapy for Overactive Bladder - URO-902 Safety and Efficacy Evaluation - Kenneth Peters

Details
Ken Peters joins Diane Newman to present the results of a Phase 2a trial evaluating the safety and efficacy of URO-902, an investigational gene therapy for overactive bladder. URO-902 is a plasma vector that expresses the alpha subunit of the human BK channel, which reduces bladder overactivity and leads to detrusor relaxation. The trial included women between 40 and 70 years old with urgency freq...

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR - Beyond the Abstract

Details
Patient perception of meaningful reductions in bothersome symptoms of overactive bladder (OAB) is lacking. In the phase 3 EMPOWUR trial, vibegron significantly reduced the average daily number of micturitions, urgency episodes, and urge urinary incontinence (UUI) episodes vs placebo. This analysis assessed the meaningfulness of reductions in clinical endpoints observed in EMPOWUR using the patient...

Mechanistic Pathway Through Which Saphenous Nerve Stimulation Can Modulate Bladder Function - Paul Yoo

Details
Joining Diane Newman is Paul Yoo to discuss his presentation from this year's SUFU annual meeting on saphenous nerve stimulation. In this particular study, Dr. Yoo's lab was interested in the mechanistic pathway through which saphenous nerve stimulation can modulate bladder function, and how this could be translated to patients with overactive bladder. Biographies: Paul Yoo, Ph.D., PEng, Associate...